Impact of Immune response-associated gene polymorphisms on tumor response in rectal cancer patients treated with capecitabine +/- oxaliplatine and radiation in the ACCORD-12/PRODIGE-2 phase III trial
B. Valerie(Institut Gustave Roussy), Pierre Laurent‐Puig(Inserm), Isabelle Miran(Inserm), Sophie Gourgou(Université de Montpellier), Ludovic Bigot(Inserm), D. Azria(Inserm), Béata Juzyna(UniCancer Group), JP Gérard(Centre Antoine Lacassagne), Jean‐François Seitz(Aix-Marseille Université), Caroline Mollévi(Inserm), Nathalie Chaput(Institut Gustave Roussy)
Cited by 0
Related Papers
The consensus molecular subtypes of colorectal cancer
|Nature Medicine|2015|5.3k
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.9k
Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer
|New England Journal of Medicine|2003|2.1k
Preoperative Radiotherapy With or Without Concurrent Fluorouracil and Leucovorin in T3-4 Rectal Cancers: Results of FFCD 9203
|Journal of Clinical Oncology|2006|1.7k